US EditionPulmonary Arterial Hypertension Market to Reach $9.35bn Across 7MM by 2034 - Pharmaceutical Technology
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Pulmonary arterial hypertension market to reach $9.3 bn in 7MM by 2034 - Express Pharma
The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 2.0 per cent from $7.6 billion in 2024 to $9.3 billion in 2034, driven by the adoption of triple combination therapy, novel prostacyclin formulations, and the entry of disease-modifying therapies, according to GlobalData. GlobalData’s latest report, “Pulmonary Arterial Hypertension: Seven-Market Drug…
Pulmonary arterial hypertension market to reach $9.3 billion in 7MM by 2034, forecasts GlobalData
The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 2.0% from $7.6 billion in 2024 to $9.3 billion in 2034, driven by the adoption of triple combination therapy, novel prostacyclin formulations, and the entry of disease-modifying therapies, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Pulmonary Arterial H…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
